RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $40
RBC Capital analyst Lisa Walter maintains $4D Molecular Therapeutics(FDMT.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 33
4D Molecular Therapeutics (FDMT) Receives a Buy From RBC Capital
The Latest Analyst Ratings For 4D Molecular Therapeutics
Cantor Fitzgerald Reiterates Overweight on 4D Molecular Therapeutics
Wall Street Analysts Think 4D Molecular Therapeutics (FDMT) Could Surge 225.1%: Read This Before Placing a Bet
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), 4D Molecular Therapeutics (FDMT) and Cullinan Management (CGEM)
Buy Rating Affirmed for 4D Molecular Therapeutics Amidst Strong Financials and Promising Pipeline
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
4D Molecular Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
4D Molecular Therapeutics Fabry Candidate Clinical Hold Lifted
Analysts Conflicted on These Healthcare Names: Senseonics Holdings (SENS), PepGen Inc. (PEPG) and 4D Molecular Therapeutics (FDMT)
RBC Capital Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), 4D Molecular Therapeutics (FDMT) and Carisma Therapeutics (CARM)
4D Molecular Therapeutics GAAP EPS of -$0.63 Beats by $0.06, Revenue of $0.01M Misses by $0.68M
4D Molecular Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | 4D Molecular Therapeutics Q2 Operating Expenses USD 42.461 Million